Bank of America Cuts DaVita (NYSE:DVA) Price Target to $140.00

DaVita (NYSE:DVA) had its price objective cut by Bank of America from $145.00 to $140.00 in a research note published on Wednesday,Benzinga reports. They currently have an underperform rating on the stock.

Several other equities research analysts have also recently commented on DVA. Truist Financial set a $148.00 price target on shares of DaVita in a research report on Friday, August 8th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Friday, August 22nd. Finally, Barclays cut their price target on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita has an average rating of “Reduce” and a consensus target price of $158.00.

DaVita Trading Down 0.1%

DVA opened at $133.08 on Wednesday. The stock has a market capitalization of $9.52 billion, a P/E ratio of 13.09, a P/E/G ratio of 0.95 and a beta of 1.13. DaVita has a 12 month low of $126.07 and a 12 month high of $179.60. The firm’s fifty day simple moving average is $138.45 and its 200 day simple moving average is $141.54. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the previous year, the firm posted $2.00 EPS. The firm’s revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company’s stock, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DVA. Man Group plc grew its stake in DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after buying an additional 269,081 shares during the last quarter. GAMMA Investing LLC grew its stake in DaVita by 14,695.8% in the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company’s stock valued at $35,919,000 after buying an additional 233,222 shares during the last quarter. Norges Bank acquired a new position in DaVita in the 2nd quarter valued at about $32,986,000. Doma Perpetual Capital Management LLC grew its stake in DaVita by 172.3% in the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock valued at $44,110,000 after buying an additional 182,476 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in DaVita in the 2nd quarter valued at about $21,554,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.